Orthocell (ASX:OCC) Expands Global Reach With Strong Revenue Momentum

Highlights

• Record annual revenue reflects expanding commercial footprint.

• Remplir adoption continues to grow across key international markets.

• Strong financial position supports global expansion strategy.

Orthocell continues to strengthen its position in regenerative medicine through growing demand for its flagship products, expanding international market access, increasing hospital adoption, and advancing regulatory milestones across multiple regions.

Orthocell (ASX:OCC) continues to strengthen its presence in regenerative medicine after reporting another year of revenue growth, highlighting the growing acceptance of its flagship nerve repair product across Australia and international markets. The company's latest update reflects expanding commercial activity, broader hospital engagement, and increasing surgeon adoption, reinforcing its position among innovative healthcare companies listed on the Australian market.

The latest financial performance also demonstrates how Orthocell is steadily transforming research and product innovation into commercial success while preparing for wider international expansion.

Growing Commercial Momentum Continues

Orthocell delivered its strongest annual financial performance to date, supported by increasing demand for both Remplir and Striate+ across domestic and overseas markets.

The latest results underline consistent commercial execution as product adoption continues to expand across multiple healthcare systems. Growing hospital participation, increasing surgeon confidence, and expanding distribution networks have all contributed to stronger revenue generation throughout the financial year.

Rather than relying on a single market, Orthocell continues building diversified revenue streams across several countries, providing greater long-term commercial resilience.

The company's commercial strategy remains focused on increasing market access while strengthening relationships with hospitals, healthcare providers and medical specialists.

Expanding Footprint Across the United States

The United States remains one of the most important growth markets for Orthocell's regenerative medicine portfolio.

Commercial rollout of Remplir continued to gain momentum as more hospitals introduced the product into clinical practice while additional surgeons adopted the nerve repair device during routine procedures.

Expansion of the distributor network has significantly broadened market coverage, allowing Orthocell to engage with more healthcare facilities across the country.

Improved hospital access has also created greater awareness among medical professionals, supporting ongoing education and product adoption initiatives.

The company's continued investment in distributor partnerships appears to be delivering meaningful commercial progress, helping establish a stronger foundation for future growth across the world's largest healthcare market.

Hospital Adoption Continues to Rise

One of the strongest indicators of commercial progress is the increasing number of hospitals integrating Remplir into surgical practice.

As healthcare institutions become more familiar with the product's clinical applications, additional facilities are completing internal approval processes before introducing the device into patient care.

Hospital approvals are an important milestone because they enable surgeons to access the product more efficiently while supporting wider clinical use across different departments.

Growing institutional confidence also creates opportunities for repeat procedures and broader adoption across healthcare networks.

This expanding hospital presence reflects increasing acceptance of regenerative medicine solutions in peripheral nerve repair.

Surgeon Confidence Drives Product Adoption

Surgeon engagement remains another major driver of Orthocell's commercial expansion.

Medical specialists continue incorporating Remplir into nerve repair procedures as familiarity with the technology increases through clinical experience and professional education.

Repeat usage by surgeons often represents an important commercial milestone because it demonstrates confidence developed through real-world clinical practice.

As more surgeons gain experience using the product, knowledge sharing within the medical community can further support broader adoption across hospitals and healthcare systems.

Orthocell continues investing in education programs designed to increase awareness of its regenerative medicine platform among healthcare professionals.

Distribution Network Creates Wider Market Access

Building an effective distribution network remains central to Orthocell's international growth strategy.

Broader geographic coverage enables hospitals and surgeons to access products more efficiently while improving customer support throughout different regions.

Distribution partners also assist with education initiatives, hospital onboarding and clinical engagement, helping accelerate product awareness.

The expanding commercial infrastructure provides Orthocell with greater capacity to introduce its products into additional healthcare facilities while supporting long-term market development.

This wider commercial reach is expected to remain an important contributor as international operations continue expanding.

Strong Financial Position Supports Expansion

Orthocell finished the financial year with a healthy liquidity position, providing financial flexibility to continue executing its long-term commercial strategy.

Available funding allows the company to invest across several strategic priorities without immediate reliance on additional capital raising.

Current investment priorities include:

• Expanding commercial activities.

• Increasing manufacturing capability.

• Supporting research and development.

• Advancing regulatory submissions.

• Improving production efficiency.

• Strengthening international distribution.

A solid balance sheet enables management to continue focusing on business expansion while pursuing sustainable long-term growth.

International Expansion Continues

Outside Australia and the United States, Orthocell continues establishing commercial pathways across several international markets.

Recently appointed distribution partners are expected to strengthen product availability while introducing Remplir into additional healthcare systems.

International sales continue becoming a larger contributor to overall company revenue as global awareness of the technology increases.

Expansion across multiple regions also helps diversify commercial exposure, reducing reliance on any single healthcare market.

Orthocell's international strategy reflects a long-term approach focused on steady geographic expansion supported by regulatory approvals and local distribution partnerships.

Regulatory Progress Opens New Opportunities

Regulatory approvals remain an important component of Orthocell's international growth plans.

The company continues progressing approval pathways across additional global healthcare jurisdictions, creating opportunities to introduce Remplir into new medical markets.

Successful regulatory milestones would allow Orthocell to access larger patient populations while supporting broader commercial distribution.

The company also continues progressing submissions through relevant regulatory authorities, maintaining momentum toward wider international availability.

Regulatory expansion remains a key pillar supporting the company's global commercial strategy.

Manufacturing Capacity Supports Future Demand

As commercial activity increases, manufacturing capability becomes increasingly important.

Orthocell continues investing in production capacity to ensure sufficient supply as hospital demand expands across multiple countries.

Manufacturing improvements also focus on operational efficiency while maintaining product quality and regulatory compliance.

Scalable production capability positions the business to respond effectively as commercial adoption accelerates across international markets.

These operational investments support both current demand and future expansion opportunities.

Healthcare Networks Create Broader Access

Orthocell recently expanded access through additional healthcare networks, increasing the availability of Remplir across specialised medical institutions.

Broader healthcare participation introduces the product to larger groups of surgeons while supporting treatment access for more patients requiring peripheral nerve repair.

Expansion into specialised healthcare systems also demonstrates increasing confidence in the company's regenerative medicine platform.

These developments strengthen Orthocell's commercial foundation while creating additional opportunities for long-term product adoption.

New Clinical Applications Continue Emerging

Orthocell is also exploring broader clinical applications for Remplir beyond existing procedures.

Growing use within nerve-sparing prostate surgery illustrates how expanding clinical evidence may support wider adoption across additional surgical specialties.

As healthcare professionals continue evaluating different treatment applications, new opportunities could emerge within regenerative medicine.

The company continues compiling clinical performance information to support future medical publications and broader awareness within the surgical community.

Expanding clinical use may strengthen the overall commercial opportunity for the product.

Striate+ Continues International Progress

Alongside Remplir, Orthocell continues advancing the commercial rollout of Striate+ across additional international markets.

Recent regulatory progress has opened new opportunities for future product launches through established global distribution partnerships.

Diversifying the commercial portfolio allows Orthocell to generate revenue from multiple regenerative medicine products while strengthening its presence within dental and surgical markets.

The continued expansion of Striate+ complements the company's broader international strategy.

Innovation Pipeline Remains Active

Orthocell continues investing beyond its existing commercial portfolio.

Development work is progressing on additional regenerative medicine technologies based on the company's collagen platform, creating opportunities for future product diversification.

New product development supports long-term business growth while expanding Orthocell's addressable healthcare markets.

Continued research and regulatory activity demonstrate the company's commitment to building a broader regenerative medicine platform over time.

Position Within Australia's Healthcare Sector

Orthocell remains part of Australia's growing biotechnology and healthcare industry, an area attracting ongoing investor attention for its focus on medical innovation and commercial expansion.

Healthcare companies operating within broader Australian market benchmarks often benefit from increasing international recognition as their commercial operations mature. Businesses that expand globally may also attract interest from investors monitoring segments of the ASX 300.

Investors following healthcare companies frequently compare commercial progress alongside broader market trends, including businesses associated with ASX 200, particularly those demonstrating expanding international operations and growing product portfolios.

Income-focused market participants exploring healthcare opportunities may also monitor broader market themes through ASX dividend stocks while evaluating companies across different sectors of the Australian share market.

Meanwhile, companies demonstrating commercial execution and global expansion often become part of broader discussions surrounding leading Australian healthcare businesses represented across the ASX 100.

Looking Ahead

Orthocell enters the new financial year with strong commercial momentum supported by expanding hospital adoption, growing surgeon engagement, wider international distribution and ongoing regulatory progress.

The company continues focusing on increasing market penetration across the United States while advancing regulatory pathways into additional global regions.

Alongside continued investment in manufacturing capacity and product innovation, Orthocell is positioning itself for further international commercial development.

With multiple growth initiatives progressing simultaneously, the business remains focused on strengthening its presence within the global regenerative medicine industry while expanding access to its product portfolio across new healthcare markets.